抗糖尿病薬の世界市場分析:製品別(インスリン、ビグアニド、チアゾロジンジオン、GLP-アゴニスト、スルホニル尿素、DPP-4阻害剤、SGLT-2、アルファ – グルコシダーゼ阻害剤、メグリチニド)、セグメント予測 -2020...市場調査レポートについてご紹介

【英文タイトル】Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

Chapter 1. Executive Summary

1.1. Antidiabetics– Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Antidiabetics Industry Outlook

2.1. Market Segmentation

2.2. Market size and growth prospects

2.3. Antidiabetics – Market dynamics

2.3.1. Market driver analysis

2.3.1.1 Growing prevalence of diabetes

2.3.1.2 Presence of a strong product pipeline portfolio

2.3.1.3 Growing prevalence of lifestyle induced disorders such as obesity

2.3.2. Market Restraint Analysis

2.3.2.1. High insulin prices

2.4. Key Opportunities Prioritized

2.5. Industry Analysis – Porter’s

2.6. Antidiabetics – PESTEL analysis

2.7. Antidiabetics market – Pipeline overview

Chapter 3. Antidiabetics Product Outlook

3.1. Antidiabetics market share by product, 2013 & 2020

3.2. Insulin

3.2.1. Insulin market share, by product, 2013 & 2020

3.2.2. Rapid acting analog market

3.2.2.1. Rapid acting analog market, 2012 – 2020 (USD Million)

3.2.3. Long acting analog market

3.2.3.1 Long acting analog market, 2012 – 2020 (USD Million)

3.2.4. Premixed analog market

3.2.4.1 Premixed analog market, 2012 – 2020 (USD Million)

3.2.5. Premixed insulin market

3.2.5.1. Premixed insulin market, 2012 – 2020 (USD Million)

3.2.6. Short acting insulin market

3.2.6.1. Short acting insulin market, 2012 – 2020 (USD Million)

3.2.7. Intermediate acting insulin market

3.2.7.1 Intermediate acting insulin market, 2012 – 2020 (USD Million)

3.3. Other antidiabetics

3.4. Alpha glucosidase inhibitors

3.4.1. Alpha glucosidase inhibitors market, 2012 – 2020 (USD Million)

3.5. Biguanides

3.5.1. Biguanides market, 2012 – 2020 (USD Million)

3.6. Sulphonylureas

3.6.1. Sulphonylureas market, 2012 – 2020 (USD Million)

3.7. GLP 1 (Glucagon like peptide) agonists

3.7.1. GLP 1 agonist market, 2012 – 2020 (USD Million)

3.8. DPP – 4 (Dipeptyl peptides) inhibitors

3.8.1. DPP-4 market, 2012 – 2020 (USD Million)

3.9. Meglitinides

3.9.1. Meglitinides market, 2012 – 2020 (USD Million)

3.10. SGLT – 2 (sodium glucose transport proteins) inhibitors

3.10.1. SGLT – 2 inhibitors market, 2012 – 2020 (USD Million)

3.11. Thiazolodinediones

3.11.1. Thiazolodinediones market, 2012 – 2020 (USD Million)

Chapter 4. Antidiabetics Regional Outlook

4.1. Antidiabetics market share, by region, 2013 & 2020

4.2. North America antidiabetics market

4.2.1. North America antidiabetics market, 2012 – 2020 (USD Million)

4.3. Europe antidiabetics market

4.3.1. Europe antidiabetics market, 2012 – 2020 (USD Million)

4.4. Asia Pacific antidiabetics market

4.4.1. Asia Pacific antidiabetics Market, 2012 – 2020 (USD Million)

4.5. RoW antidiabetics market

4.5.1. RoW antidiabetics market, 2012 – 2020 (USD Million)

Chapter 5. Competitive Landscape

5.1 Sanofi Aventis

5.1.1 Company Overview

5.1.2 Financial Performance

5.1.3 Product Benchmarking

5.1.4 Strategic Initiatives

5.2 Takeda Pharmaceuticals

5.2.1 Company Overview

5.2.2 Financial Performance

5.2.3 Product Benchmarking

5.2.4 Strategic Initiatives

5.3 Eli Lilly

5.3.1 Company Overview

5.3.2 Financial Performance

5.3.3 Product Benchmarking

5.3.4 Strategic Initiatives

5.4 Oramed Pharmaceuticals Inc.

5.4.1 Company Overview

5.4.2 Financial Performance

5.4.3 Product Benchmarking

5.4.4 Strategic Initiatives

5.5 Merck & Co. Inc.

5.5.1 Company Overview

5.5.2 Financial Performance

5.5.3 Product Benchmarking

5.5.4 Strategic Initiatives

5.6 Novo Nordisk

5.6.1 Company Overview

5.6.2 Financial Performance

5.6.3 Product Benchmarking

5.6.4 Strategic Initiatives

5.7 Bristol-Myers Squibb

5.7.1 Company Overview

5.7.2 Financial Performance

5.7.3 Product Benchmarking

5.7.4 Strategic Initiatives

5.8 Halozyme Therapeutics

5.8.1 Company Overview

5.8.2 Financial Performance

5.8.3 Product Benchmarking

5.8.4 Strategic Initiatives

5.9 Pfizer

5.9.1 Company Overview

5.9.2 Financial Performance

5.9.3 Product Benchmarking

5.9.4 Strategic Initiatives

Chapter 6. Methodology and Scope

6.1. Research Methodology

6.2. Research Scope & Assumptions

6.3. List of Data Sources

List of Tables

1. Antidiabetics – Industry Summary & Critical Success Factors (CSFs)
2. Global insulin market, by product, 2012 – 2020 (USD Million)
3. Global other antidiabetics market, by product, 2012 – 2020 (USD Million)
4. Global antidiabetics market, by region, 2012 – 2020 (USD Million)
5. Antidiabetics – Key market driver analysis
6. North America diabetes prevalence (national prevalence %), 2013 & 2035
7. Europe diabetes prevalence (national prevalence %), 2013 & 2035
8. Latin America diabetes prevalence (national prevalence %), 2013 & 2035
9. MENA and Africa diabetes prevalence (national prevalence %), 2013 & 2035
10. CIS diabetes prevalence (national prevalence %), 2013 & 2035
11. Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035
12. Antidiabetics – Key market restraint analysis
13. Antidiabetics market – Pipeline overview
14. Insulin types and brands
15. List of brands of alpha glucosidase for diabetes
16. List of major brands of biguanides for diabetes
17. Brands and generic names of sulphonylureas for diabetes
18. Brands and generic names of GLP-1 for diabetes
19. List of major brands of DPP-4 for diabetes
20. List of major drugs of meglitinides for diabetes
21. List of major drugs of SGLT-2 for diabetes
22. North America insulin market, by product, 2012 – 2020 (USD Million)
23. North America insulin market, by application, 2012 – 2020 (USD Million)
24. North America other antidiabetics market, by product, 2012 – 2020 (USD Million)
25. Europe insulin market, by product, 2012 – 2020 (USD Million)
26. Europe insulin market, by application, 2012 – 2020 (USD Million)
27. Europe other antidiabetics market, by product, 2012 – 2020 (USD Million)
28. Asia Pacific insulin market, by product, 2012 – 2020 (USD Million)
29. Asia Pacific insulin market, by application, 2012 – 2020 (USD Million)
30. Asia pacific other antidiabetics market, by product, 2012 – 2020 (USD Million)
31. RoW insulin market, by product, 2012 – 2020 (USD Million)
32. RoW insulin market, by application, 2012 – 2020 (USD Million)
33. RoW other antidiabetics market, by product, 2012 – 2020 (USD Million)

List of Figures

1. Antidiabetics market segmentation
2. Global antidiabetics market revenue, 2012 – 2020 (USD Million)
3. Antidiabetics: Market dynamics
4. Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
5. Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
6. Key opportunities prioritized
7. Antidiabetics market – Porter’s analysis
8. Antidiabetics market – PESTEL analysis
9. Antidiabetics market share by product, 2013 & 2020
10. Insulin market share by product, 2013 & 2020
11. Rapid acting analog market, 2012 – 2020 (USD Million)
12. Long acting analog market, 2012 – 2020 (USD Million)
13. Premixed analog market, 2012 – 2020 (USD Million)
14. Premixed insulin market, 2012 – 2020 (USD Million)
15. Short acting insulin market, 2012 – 2020 (USD Million)
16. Intermediate acting insulin market, 2012 – 2020 (USD Million)
17. Global alpha glucosidase inhibitors market, 2012 – 2020 (USD Million)
18. Global biguanides market, 2012 – 2020 (USD Million)
19. Global sulphonylureas market, 2012 – 2020 (USD Million)
20. Global GLP 1 agonist market, 2012 – 2020 (USD Million)
21. Global DPP-4 market, 2012 – 2020 (USD Million)
22. Global meglitinides market, 2012 – 2020 (USD Million)
23. Global SGLT – 2 inhibitors market, 2012 – 2020 (USD Million)
24. Global thiazolodinediones market, 2012 – 2020 (USD Million)
25. Antidiabetics market share by region, 2013 & 2020
26. North America antidiabetics market, 2012 – 2020 (USD Million)
27. Europe antidiabetics market, 2012 – 2020 (USD Million)
28. Asia Pacific antidiabetics market, 2012 – 2020 (USD Million)
29. RoW antidiabetics market, 2012 – 2020 (USD Million)


【レポート販売概要】

■ タイトル:抗糖尿病薬の世界市場分析:製品別(インスリン、ビグアニド、チアゾロジンジオン、GLP-アゴニスト、スルホニル尿素、DPP-4阻害剤、SGLT-2、アルファ – グルコシダーゼ阻害剤、メグリチニド)、セグメント予測 -2020
■ 英文:Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020
■ 発行日:2015年1月1日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707051
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。